Background In 2012, a European initiative called Single Hub and Access point for pediatric
Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic …

Objectives The European Single Hub and Access point for paediatric Rheumatology in Europe
initiative aimed to optimize care for children with rheumatic diseases. Kawasaki disease (…

Background Macrophage activation syndrome (MAS) is a severe and potentially lethal
complication of several inflammatory diseases but seems particularly linked to systemic juvenile …

… 30 (Pedi 30) criteria for improvement at week 14 (63.8% and 49.2%, respectively), the
between‐group difference in this primary efficacy end point was not statistically significant (P = …

Spirochete bacteria of the Borrelia burgdorferi sensu lato complex cause Lyme borreliosis.
The three pathogenic subspecies Borrelia garinii, Borrelia afzelii, and Borrelia burgdorferi …

OBJECTIVE: To find the incidence of juvenile arthritis according to the ILAR and EULAR
criteria within defined areas in the Nordic countries, and to study the validity of the ILAR and …

Background We compared the safety and efficacy of leflunomide with that of methotrexate in
the treatment of polyarticular juvenile rheumatoid arthritis in a multinational, randomized, …

Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …

… had glaucoma (p = 0.007). There were no differences between etanercept and infliximab
groups in visual acuity either at the baseline (p = 0.81) or at the end of the follow-up (p = 0.90). …

… in both panels A and C were significant; p<0.0001 and p=0.002, respectively. Error bars …
p=0.003). Drug survival rates were higher for TNF than for methotrexate (p=0.001) or COMBO (p…